NCT00440141

Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering will be randomized to receive either brimonidine 0.1% or brinzolamide 1% three-times daily as adjunctive therapy to latanoprost 0.005%

Conditions

• Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	latanoprost 0.005% eye drops and brimonidine 0.1% eye drops	latanoprost 0.005%, 1 drop nightly for 3 months and brimonidine 0.1% three-times daily for 3 months
DRUG	latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops	latanoprost 0.005% 1 drop nightly for 3 months AND brinzolamide 1.0% 1% three-times daily for 3 months

Timeline

• Start date: 2006-07-01
• Primary completion: 2007-03-01
• Completion: 2007-03-01
• First posted: 2007-02-26
• Last updated: 2008-01-02

Locations

1 site across 1 country: United States